{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:47:32Z","timestamp":1773064052615,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic kidney disease (<jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>) was a relative contraindication to hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) treatment in the interferon\/ribavirin era.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To determine the efficacy, tolerability and safety of sofosbuvir\/ledipasvir (<jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content>) and paritaprevir\/ritonavir\/ombitasvir\/dasabuvir (Pr<jats:styled-content style=\"fixed-case\">OD<\/jats:styled-content>) regimens in persons with <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified persons initiated on a <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content> or Pr<jats:styled-content style=\"fixed-case\">OD<\/jats:styled-content> regimen from October 30, 2014 to April 30, 2016. We excluded those with missing <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype or <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content> values. We determined treatment completion and sustained virologic response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>) rates, and proportion developing worsening renal function or grade 3\/4 haematologic toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 13\u00a0663 persons on <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content>\u00b1ribavirin, 14% and 1% persons had <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> Stage 3 and 4\u20105 respectively, 67.8% completed treatment, 98.2% achieved <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>. Treatment completion or <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rates did not decline with advanced <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> or ribavirin administration. Among 3961 persons on Pr<jats:styled-content style=\"fixed-case\">OD<\/jats:styled-content>\u00b1ribavirin, 9% and 3% persons had <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> Stage 3 and 4\u20105, respectively, 74.0% completed treatment and 98.2% achieved <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>. A decrease in treatment completion rates was seen in <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> stage 4\u20105 and those on ribavirin, but this did not impact <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rates. A &gt;10\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> drop in <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content> from baseline was observed in 30%\u201038% of persons with baseline <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content> \u226560\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>, but in only 0%\u20106% with <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>4\u20105. Grade 3\/4 anaemia was more frequent in persons with <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>4\u20105, but ribavirin co\u2010administration did not appear to affect this.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content> and Pr<jats:styled-content style=\"fixed-case\">OD<\/jats:styled-content> achieved high <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rates in <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> population. Treatment completion rates were lower than expected. A decline in <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content> and development of anaemia were observed in a substantial proportion of persons, but the clinical implications remain unclear.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.14799","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T11:35:26Z","timestamp":1527161726000},"page":"35-43","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effectiveness, treatment completion and safety of sofosbuvir\/ledipasvir and paritaprevir\/ritonavir\/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study"],"prefix":"10.1111","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-1826","authenticated-orcid":false,"given":"A. A.","family":"Butt","sequence":"first","affiliation":[{"name":"VA Pittsburgh Healthcare System Pittsburgh PA USA"},{"name":"Weill Cornell Medical College New York NY USA"},{"name":"Weill Cornell Medical College Doha Qatar"},{"name":"Department of Medicine Hamad Medical Corporation Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Ren","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System Pittsburgh PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Puenpatom","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. North Wales PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Arduino","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. North Wales PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. North Wales PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A\u2010B.","family":"Abou\u2010Samra","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College New York NY USA"},{"name":"Weill Cornell Medical College Doha Qatar"},{"name":"Department of Medicine Hamad Medical Corporation Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13036"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.08.004"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw567"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13790"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312444"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30116-4"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.078"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13837"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13102"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3918-z"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/764540"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23000"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.09.023"},{"key":"e_1_2_7_17_1","first-page":"S1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"National Kidney Foundation","year":"2013","journal-title":"Kidney Int"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.6502"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20289"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832bd7af"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00885.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2148"},{"key":"e_1_2_7_23_1","volume-title":"Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System","author":"WHO"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04741.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i26.4191"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.133884"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34613"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12276"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13748"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.14799","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.14799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T10:01:00Z","timestamp":1694340060000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.14799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/apt.14799"],"URL":"https:\/\/doi.org\/10.1111\/apt.14799","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,24]]},"assertion":[{"value":"2018-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}